Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar-Reference-Cited by-同舟云学术

Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar

Published:2013-10-03 Issue:6 Volume:134 Page:1484-1494
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Chuan Tang Seng¹,Nguyen Luan N.¹,Sparidans Rolf W.²,Wagenaar Els¹,Beijnen Jos H.²³,Schinkel Alfred H.¹

Affiliation:

1. Division of Molecular Oncology; The Netherlands Cancer Institute; Amsterdam The Netherlands

2. Department of Pharmaceutical Sciences; Division of Pharmacoepidemiology and Clinical Pharmacology; Faculty of Science; Utrecht University; Utrecht The Netherlands

3. Department of Pharmacy and Pharmacology; Slotervaart Hospital; Amsterdam The Netherlands

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference44 articles.

1. Global patterns of cancer incidence and mortality rates and trends;Jemal;Cancer Epidemiol Biomarkers Prev,2010

2. Lung cancer;Herbst;N Engl J Med,2008

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Oncogenic mutations of ALK kinase in neuroblastoma;Chen;Nature,2008

5. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer;Koivunen;Clin Cancer Res,2008

Cited by 128 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Crizotinib resistance reversal in ALK-positive lung cancer through zeolitic imidazolate framework-based mitochondrial damage;Acta Biomaterialia;2024-09

2. Spotlight on the treatment of non‐small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives;International Journal of Cancer;2024-07-03

3. Prediction of trough concentration and ALK occupancy in plasma and cerebrospinal fluid using physiologically based pharmacokinetic modeling of crizotinib, alectinib, and lorlatinib;Frontiers in Pharmacology;2023-11-22

4. Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma;Cell Death & Disease;2023-11-16

5. Syntheses and evaluation of acridone derivatives as anticancer agents targeting Kras promoter i-motif structure;Bioorganic Chemistry;2023-07